Rong Li

Rong Li


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2018 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
GYGuangyi Yang
Guangyi Yang
JLJing Li
Jing Li
YCYouli Cai
Youli Cai
ZYZhonghua Yang
Zhonghua Yang
RLRong Li
Rong Li
WFWenjun Fu
Wenjun Fu

25 February 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
XWXianliang Wang
Xianliang Wang
ZZZhiqiang Zhao
Zhiqiang Zhao
JMJingyuan Mao
Jingyuan Mao
TDTinghai Du
Tinghai Du
YCYuanping Chen
Yuanping Chen
CLChunxiang Liu
Chunxiang Liu
Background. Shenfu injection (SFI) has shown a remarkable therapeutic effect in patients with chronic heart failure (CHF) during the acute phase of symptom aggravation since it became commercially available in 1987. However, the therapeutic effect of SFI has not been validated in a standard clinical study. As a pilot clinical trial, this study aimed to evaluate the safety and efficacy of SFI for treatment of CHF patients during the acute phase. Methods. A total of 160 patients experiencing acute phase CHF were enrolled in this study and randomly assigned to receive the placebo (placebo group, 150 ml glucose (GS)) or SFI (SFI group, 50 ml SFI + 100 ml GS) in addition to their standard medications for CHF treatment. The treatment lasted for 7 ± 1 days, and the follow-up continued for 28 ± 3 days after treatment. The primary endpoints were New York Heart Association (NYHA) classification and Traditional Chinese Medicine (TCM) syndrome scores. Results. After 7±1 days of treatment, the efficacy of SFI according to improvements in NYHA and TCM syndrome scores in the SFI group (78.38% and 89.19%, respectively) was significantly higher than that in the placebo group (61.43% and 60.00%, respectively; P<0.05). The SFI group had a longer increase in amplitude than the placebo group (113.00 m versus 82.99 m, P<0.05). The incidence of adverse events and other safety indices showed no significant differences between the two groups. Conclusion. SFI combined with conventional therapy for treatment of CHF during acute symptom aggravation ameliorated the cardiac dysfunction and clinical symptoms and improved the patients’ quality of life without any significant AEs compared with the conventional therapy alone.

8 August 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
LLLiwen Lin
Liwen Lin
HXHonglin Xu
Honglin Xu
ZYZhengyang Yao
Zhengyang Yao
XZXianyou Zeng
Xianyou Zeng
LKLiang Kang
Liang Kang
RLRong Li
Rong Li
Chronic heart failure (CHF) is a severe consequence of cardiovascular disease, marked by cardiac dysfunction. Jin-Xin-Kang (JXK) is a traditional Chinese herbal formula used for the treatment of CHF. This formula consists of seven medicinal herbs, including Ginseng (Ginseng quinquefolium (L.) Alph.Wood), Astragali Radix (Astragalus membranaceus (Fisch.) Bunge), Salvia miltiorrhiza (Salvia miltiorrhiza Bunge), Descurainiae Semen Lepidii Semen (Descurainia sophia (L.) Webb ex Prantl), Leonuri Herba (Leonurus japonicus Houtt.), Cinnamomi Ramulus (Cinnamomum cassia (L.) J.Presl), and Ilex pubescens (Ilex pubescens Hook. & Arn.). Its clinical efficacy has been validated through prospective randomized controlled studies. However, the specific mechanisms of action for this formula have yet to be elucidated. This study aimed to investigate the effect of JXK on mitochondrial function and its mechanism in the treatment of CHF. JXK components were qualitatively analyzed using UPLC-Q-Orbitrap-MS. HF was induced in mice via transverse aortic constriction (TAC). After successful model establishment, lyophilized JXK-L (4.38 g/kg) and JXK-H (13.14 g/kg) were administered for 8 weeks. In vitro, hypertrophic myocardium was induced using angiotensin II (Ang II) for 48 h, followed by JXK-L and JXK-H treatment. Network pharmacology and molecular docking techniques were used to predict the relevant targets of JXK. Cardiac function, serum markers, and histopathological changes were evaluated to assess cardiac function. Immunofluorescence of Tomm20, mitochondrial membrane potential, and ROS were measured to assess mitochondrial dysfunction. Protein expression of calcineurin (CaN) and Drp1 in the myocardium was assessed by Western blot analysis. We detected that the active components of JXK include terpenes, glycosides, flavonoids, amino acids, and alkaloids, among others. In mice with CHF, JXK improved cardiac function and reversed ventricular remodeling. Network pharmacology indicated that JXK can inhibit the calcium signaling pathway. The molecular docking results demonstrated that the active components of JXK effectively bind with CaN. Both in vitro and in vivo experiments confirmed that JXK regulated the CaN/Drp1 pathway and alleviated mitochondrial dysfunction. JXK can inhibit the CaN/Drp1 pathway to improve mitochondrial function, and consequently treat CHF.

12 March 2025 in Phytomedicine
Verified
Journal Article
Closed access
GCGuanghong Chen
Guanghong Chen
WWWanyu Wang
Wanyu Wang
BGBaoyi Guan
Baoyi Guan
GZGuoyong Zhang
Guoyong Zhang
ZZZhimin Zhang
Zhimin Zhang
RLRong Li
Rong Li

12 May 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
YCYu-Peng Chen
Yu-Peng Chen
KWKe-Xin Wang
Ke-Xin Wang
JCJie-Qi Cai
Jie-Qi Cai
YLYi Li
Yi Li
HYHai-Lang Yu
Hai-Lang Yu
GDGuan Daogang
Guan Daogang
Stroke is a cerebrovascular event with cerebral blood flow interruption which is caused by occlusion or bursting of cerebral vessels. At present, the main methods in treating stroke are surgical treatment, statins, and recombinant tissue-type plasminogen activator (rt-PA). Relatively, traditional Chinese medicine (TCM) has widely been used at clinical level in China and some countries in Asia. Xiao-Xu-Ming decoction (XXMD) is a classical and widely used prescription in treating stroke in China. However, the material basis of effect and the action principle of XXMD are still not clear. To solve this issue, we designed a new system pharmacology strategy that combined targets of XXMD and the pathogenetic genes of stroke to construct a functional response space (FRS). The effective proteins from this space were determined by using a novel node importance calculation method, and then the key functional components group (KFCG) that could mediate the effective proteins was selected based on the dynamic programming strategy. The results showed that enriched pathways of effective proteins selected from FRS could cover 99.10% of enriched pathways of reference targets, which were defined by overlapping of component targets and pathogenetic genes. Targets of optimized KFCG with 56 components can be enriched into 166 pathways that covered 80.43% of 138 pathways of 1,012 pathogenetic genes. A component potential effect score (PES) calculation model was constructed to calculate the comprehensive effective score of components in the components-targets-pathways (C-T-P) network of KFCGs, and showed that ferulic acid, zingerone, and vanillic acid had the highest PESs. Prediction and docking simulations show that these components can affect stroke synergistically through genes such as MEK, NFκB, and PI3K in PI3K-Akt, cAMP, and MAPK cascade signals. Finally, ferulic acid, zingerone, and vanillic acid were tested to be protective for PC12 cells and HT22 cells in increasing cell viabilities after oxygen and glucose deprivation (OGD). Our proposed strategy could improve the accuracy on decoding KFCGs of XXMD and provide a methodologic reference for the optimization, mechanism analysis, and secondary development of the formula in TCM.

20 January 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
YCYu-Peng Chen
Yu-Peng Chen
KWKe-Xin Wang
Ke-Xin Wang
JCJie-Qi Cai
Jie-Qi Cai
YLYi Li
Yi Li
HYHai-Lang Yu
Hai-Lang Yu
GDGuan Daogang
Guan Daogang
Corrigendum: Detecting key functional components group and speculating the potential mechanism of Xiao-Xu-Ming decoction in treating stroke